Connect Biopharma Holdings Limited
NASDAQ:CNTBBiotechnology
-$0.09 today
- Market cap
- $50.52M
- Beta
- -0.21
- P/E (TTM)
- -4.0
- EPS (TTM)
- -$0.50
Volume 2.50M
Average 0.30M
CNTB Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Connect Biopharma Holdings LimitedNASDAQ: CNTB
Other Income / Expenses · Q4 FY2025 · quarter ended Dec 2025
Other income / expenses declines year over year
Q4 FY2025 other income / expenses of $444K fell 45.8% year over year. Over 3 fiscal years it compounded at +22.4% a year.
Context
- Other income / expenses amounted to 4360.9% of revenue in FY2025, up 4333.9 pp from a year earlier.
- Other income / expenses increased in 1 of the last 3 fiscal years.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 2.79M USD
- Year-over-year change
- -60.4%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.79M | -60.4% |
| FY2024 | 2024-12-31 | 7.05M | -0.3% |
| FY2023 | 2023-12-31 | 7.07M | +364.2% |
| FY2022 | 2022-12-31 | 1.52M | +101.5% |
| FY2021 | 2021-12-31 | (103.89M) | — |
Other Income / Expenses vs competitors
How CNTB compares with its peers on the latest reported figures
- Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -60.4% is the 7th highest of 9, against a peer median of -30.8%.
- Other income / expenses amounts to 4360.9% of revenue for CNTB, versus a peer median of 305.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $23.57M USD | -26.4% | +162.8% | 330.9% | |
IMAImageneBio Inc | LTM Mar 2026 | $10.53M USD | +5.4% | +8.8% | — |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $5M USD | -50.6% | +65.3% | — |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | $3.53M USD | +1344.0% | — | — |
| LTM Mar 2026 | $3.29M USD | -17.6% | +87.2% | — | |
| FY2025 | $2.79M USD | -60.4% | +22.4% | 4360.9% | |
| LTM Mar 2026 | $2.79M USD | -35.2% | +24.9% | 279.0% | |
| LTM Mar 2026 | -€440.14K EUR | -104.4% | -1.4% | 1500.6% | |
| LTM Mar 2026 | -$38.64M USD | -613.7% | — | 38.8% | |
| Peer median (excluding CNTB) | — | -30.8% | +45.1% | 305.0% | |
Competitors are the stored peer set for CNTB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 26.03M | 64K |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 26.03M | 64K |
| Gross Margin | — | — | — | 100.0% | 100.0% |
| Research & Development | 80.5M | 96.63M | 53M | 29.26M | 37.8M |
| Selling, General & Admin | 19.01M | 20.81M | 16.05M | 19.23M | 20.34M |
| Operating Expenses | 98.11M | 119.32M | 69.06M | 48.49M | 58.14M |
| Depreciation & Amortization | 634K | 1.03M | 720K | 660K | 704K |
| EBITDA | (201.36M) | (116.74M) | (61.27M) | (14.75M) | (54.58M) |
| EBITDA Margin | — | — | — | -56.6% | -85279.7% |
| Operating Income | (98.11M) | (119.32M) | (69.06M) | (22.45M) | (58.07M) |
| Operating Margin | — | — | — | -86.2% | -90740.6% |
| Interest Income | 97.67K | 1.56M | 5.2K | 4.45M | 2.27M |
| Interest Expense | 6.91K | 21.03K | 0 | 0 | 0 |
| Other Income / Expenses | (103.89M) | 1.52M | 7.07M | 7.05M | 2.79M |
| Income Before Tax | (202M) | (117.79M) | (61.99M) | (15.41M) | (55.28M) |
| Pre-Tax Margin | — | — | — | -59.2% | -86379.7% |
| Income Tax Expense | 266K | 298K | 120K | 223K | 197K |
| Net Income | (202.27M) | (118.09M) | (62.11M) | (15.63M) | (55.48M) |
| Net Margin | — | — | — | -60.0% | -86687.5% |
| EPS (Basic) | (25.00) | (14.50) | (1.08) | (0.28) | (1.00) |
| EPS (Diluted) | (25.00) | (14.50) | (1.08) | (0.28) | (1.00) |
| Weighted Avg Shares | 52.27M | 55.04M | 55.07M | 55.21M | 55.66M |
| Weighted Avg Shares (Diluted) | 52.27M | 55.04M | 55.07M | 55.21M | 55.66M |
Connect Biopharma Holdings Limited
NASDAQ:CNTB
Intrinsic Alpha fair value
Locked
Current Price
$0.80
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.